In patients with estrogen receptor (ER)-positive breast cancer, endocrine therapy, which works by either blocking estrogens from attaching to the ER or by deprivation of estrogen, remains the mainstay of treatment. This evidence concerns the gene ESR1 and breast carcinoma.